POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer.

Year of Production:
Running Time:
Color/Sound:

2015
05:10
Color/Sound

Comments are closed.